Teva Pharmaceutical Industries (TEVA) Income towards Parent Company (2016 - 2026)

Teva Pharmaceutical Industries has disclosed Income towards Parent Company across 11 years of filings, most recently posting $366.0 million for Q1 2026.

• Quarterly Income towards Parent Company rose 71.83% year-over-year to $366.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $366.0 million (up 71.83% YoY) and the FY2025 annual result came in at $1.4 billion, up 171.12% from the prior year.
• Income towards Parent Company declined to $366.0 million in Q1 2026, from $466.0 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $466.0 million in Q4 2025 and troughed at -$2.1 billion in Q4 2022.
• A 5-year average of -$533.7 million and a median of -$506.0 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company plunged 111.53% — and 2025, when it surged 265.25%.
• Tracing TEVA's Income towards Parent Company over 5 years: stood at -$2.1 billion in 2022, then surged by 92.76% to -$154.0 million in 2023, then slumped by 83.12% to -$282.0 million in 2024, then jumped by 265.25% to $466.0 million in 2025, then fell by 21.46% to $366.0 million in 2026.
• Business Quant data shows TEVA's Income towards Parent Company at $366.0 million in Q1 2026, $466.0 million in Q4 2025, and $428.0 million in Q3 2025.